Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...   ViaDerma, Inc. (OTCQB: VDRM), a ... to market, has recently released a revolutionary new ... topical liquid tetracycline-based antibiotic that uses a patent-pending ... medication active ingredients into topical drugs. The drug ... to help prevent skin infection in minor cuts, ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Support Development,of Omega DUROS Continuous Delivery Therapy, ... Intarcia,Therapeutics, Inc., a privately held biopharmaceutical company,today ... study of omega,interferon with or without ribavirin ... C. The results demonstrate that,omega interferon in ...
... Conn., April 12, 2007 /PRNewswire-FirstCall/ --,CuraGen Corporation ... (PXD101), a histone deacetylase (HDAC) inhibitor being,investigated ... a protein,being investigated for the prevention of ... upcoming American Association for Cancer,Research (AACR) 2007 ...
Cached Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... October 30, 2014—(BRONX, NY)—Investigators at Albert Einstein ... and Montefiore Medical Center will present their ... America,s (GSA) 67th Annual Scientific Meeting. Topics include ... survival, risk factors for cognitive impairment and the ... place November 5-9, 2014 in Washington, D.C., "Einstein-Montefiore ...
(Date:10/30/2014)... – You have to be at least 2 years ... younger babies, no official U.S. guidance exists other than ... mothers exclusively breastfeed for at least the first six ... , That,s the question that motivated researchers at ... Sciences to study the eating patterns of American infants ...
(Date:10/30/2014)... October 30, 2014 Nutrition Leaders, a ... weight loss aids, and more, is currently hosting a ... is already underway, is open to U.S. residents age ... December 15, 2014. One lucky winner will then be ... a $100 gift card to NutritionLeaders.com. , Nutrition Leaders’ ...
(Date:10/30/2014)... 30, 2014 Don Allred Insurance, a ... insurance plans for North Carolina residents, is excited to ... Burlington’s Holly Hill Mall. The new branch has been ... helping customers through all facets of the insurance selection ... Insurance spokesman Scott Allred couldn’t be happier with the ...
Breaking Medicine News(10 mins):Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2
... with Exciting New Line ... of Toys, ALPHARETTA, ... Bright Starts(TM) introduces its newest collection of,toys designed to delight babies with endless ... as he or,she explores a wide range of toys, from plush pals to ...
... ORANGE, N.J., July 8 The Henry H. ... people with,disabilities, announced today two key personnel changes ... A. DeLisa, M.D., current President of Kessler,Medical Rehabilitation ... while John DeLuca, Ph.D. will become the Vice ...
... Data, Structured Reporting, Scheduling and ... OAKLAND, Calif., July 8 The University of ... suite of IT,applications to equip their CV service lines ... to integrate disparate,systems, streamline workflow, improve quality, and help ...
... Improve Quality of Patient Data System, CAMBRIDGE, ... plc (LSE: AU. or AU.L), a global leader ... Servicio,Extremeno de Salud (SES), a provider of public ... Extremadura region of Spain, has selected,Autonomy,s Meaning-based Computing ...
... GRAS announces two new important features. A brand new version ... on-the-fly photometric analysis and report generation. The second item, is a ... imaging for themselves using the G13 telescope, located in Australia (more ... ...
... MedRetreat Offers 5 Steps to Help International Medical Providers Partner With Only ... ... 8, 2008 -- As interest in medical tourism heats up ... up to cash in on the emerging industry. But international hospitals should ...
Cached Medicine News:Health News:Bright Starts(TM) Adds New Twist to Old Favorites 2Health News:Bright Starts(TM) Adds New Twist to Old Favorites 3Health News:The Henry H. Kessler Foundation Appoints New Vice President for Research and Strengthens Relationship With Current Research Luminary 2Health News:Building a Fully Integrated Cardiovascular Imaging and Information System Webinar 2Health News:Spanish Health Service Provider Selects Autonomy to Deliver Innovation Within Healthcare 2Health News:Spanish Health Service Provider Selects Autonomy to Deliver Innovation Within Healthcare 3Health News:GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems 2Health News:GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems 3Health News:An American Appeal to Overseas Hospitals 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: